Form 8-K

8-K — TELEFLEX INC

Accession: 0000096943-26-000048

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0000096943

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tfx-20260507.htm (Primary)

EX-99.1 (ex991to5-6x2026req12026ear.htm)

EX-99.2 (exhibit992to5-7x2026req1.htm)

GRAPHIC (exhibit992to5-7x2026req1001.jpg)

GRAPHIC (exhibit992to5-7x2026req1002.jpg)

GRAPHIC (exhibit992to5-7x2026req1003.jpg)

GRAPHIC (exhibit992to5-7x2026req1004.jpg)

GRAPHIC (exhibit992to5-7x2026req1005.jpg)

GRAPHIC (exhibit992to5-7x2026req1006.jpg)

GRAPHIC (exhibit992to5-7x2026req1007.jpg)

GRAPHIC (exhibit992to5-7x2026req1008.jpg)

GRAPHIC (exhibit992to5-7x2026req1009.jpg)

GRAPHIC (exhibit992to5-7x2026req1010.jpg)

GRAPHIC (exhibit992to5-7x2026req1011.jpg)

GRAPHIC (exhibit992to5-7x2026req1012.jpg)

GRAPHIC (exhibit992to5-7x2026req1013.jpg)

GRAPHIC (exhibit992to5-7x2026req1014.jpg)

GRAPHIC (exhibit992to5-7x2026req1015.jpg)

GRAPHIC (exhibit992to5-7x2026req1016.jpg)

GRAPHIC (exhibit992to5-7x2026req1017.jpg)

GRAPHIC (exhibit992to5-7x2026req1018.jpg)

GRAPHIC (exhibit992to5-7x2026req1019.jpg)

GRAPHIC (exhibit992to5-7x2026req1020.jpg)

GRAPHIC (exhibit992to5-7x2026req1021.jpg)

GRAPHIC (exhibit992to5-7x2026req1022.jpg)

GRAPHIC (exhibit992to5-7x2026req1023.jpg)

GRAPHIC (exhibit992to5-7x2026req1024.jpg)

GRAPHIC (exhibit992to5-7x2026req1025.jpg)

GRAPHIC (exhibit992to5-7x2026req1026.jpg)

GRAPHIC (exhibit992to5-7x2026req1027.jpg)

GRAPHIC (exhibit992to5-7x2026req1028.jpg)

GRAPHIC (tfxlogo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: tfx-20260507.htm · Sequence: 1

tfx-20260507

0000096943false00000969432026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) May 7, 2026

TELEFLEX INCORPORATED

(Exact name of Registrant as Specified in Its Charter)

Delaware 1-5353 23-1147939

(State or Other Jurisdiction

of Incorporation or Organization)

(Commission File Number)

(IRS Employer

Identification No.)

550 E. Swedesford Rd., Suite 400 Wayne, PA 19087

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code (610) 225-6800

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, par value $1 per share TFX New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 7, 2026, Teleflex Incorporated (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report.

In addition to the financial information included in the Press Release that has been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), the Press Release includes certain non-GAAP financial measures. These measures include pro forma adjusted revenue, pro forma adjusted constant currency revenue growth and adjusted diluted earnings per share. Pro forma adjusted revenue is based upon net revenues, adjusted to (i) exclude, depending on the period presented, the impact of products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. Pro forma adjusted constant currency revenue growth is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Adjusted diluted earnings per share is based upon diluted earnings per share available to common stockholders, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact (net of tax) of (i) restructuring and optimization charges; (ii) impairment charges, (iii) acquisition, integration and divestiture related items; (iv) separation costs related to the Company's entry into agreements to divest its Acute Care, Interventional Urology and OEM businesses (the "Strategic Divestitures"), including activities to prepare the businesses for divestiture and maintain continuity through the separation process; (v) the impact from increases in our reserves related to the Italian payback measure pertaining to prior years as described in the Press Release; (vi) other items identified in the reconciliation tables set forth in the Press Release, as applicable; (vii) certain expenditures associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; (ix) costs incurred in connection with our implementation of a new global enterprise resource planning system and related information technology transition costs; and (x) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Management uses these non-GAAP financial measures to assess the Company's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 7.01. Regulation FD Disclosure.

In connection with the conference call to be held by the Company on May 7, 2026 to discuss its financial results for the quarter ended March 31, 2026, the Company plans to reference a slide presentation, which will be made available in advance of the call through the Company’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.2, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company

under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release, dated May 7, 2026

99.2 Earnings Conference Call Slide Presentation

104 The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2026

TELEFLEX INCORPORATED

By: /s/ John R. Deren

Name: John R. Deren

Title: Executive Vice President and Chief Financial Officer

EX-99.1

Filename: ex991to5-6x2026req12026ear.htm · Sequence: 2

Document

Exhibit 99.1

FOR IMMEDIATE RELEASE May 7, 2026

Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook

Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026.

First quarter 2026 continuing operations financial summary1

•Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2

•GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period

•Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period

2026 continuing operations guidance summary1

•Maintaining GAAP revenue growth guidance range of 14.40% to 15.40%

•Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%2

•Maintaining GAAP EPS from continuing operations guidance range of $2.90 to $3.20

•Maintaining Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55

◦Includes full year impact of stranded costs estimated to be $90 million

◦Excludes expected benefits from transition services (“TS”) and manufacturing services (“MS”) agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis

◦Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million primarily funded by closing of Strategic Divestitures

"Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1 billion share repurchase authorization, while also reducing debt by $800 million to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex's position as a focused medical technologies leader and drive long-term value creation."

Mr. Randle continued, “We recently announced the appointment of Jason Weidman as President and Chief Executive Officer, effective June 8, 2026. His deep medical technology expertise and proven track record of driving growth and innovation make him well suited to lead Teleflex into its next chapter and capitalize on the opportunities ahead. Additionally, consistent with our

commitment to strong governance and creating shareholder value, we announced several actions in April, including the nomination of Michael J. Tokich to our Board of Directors, the initiation of opportunistic open-market share repurchases in the second quarter and our intent to establish a new Growth and Operating Committee of the Board.”

(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".

(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment and (b) the impact of foreign exchange.

NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding net revenues in each of the Company's global product categories for the three months ended March 31, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.

Three Months Ended % Increase / (Decrease)

March 31, 2026 March 30, 2025

Reported revenue Adjustment Pro Forma Adjusted Revenue Reported revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment impact Pro Forma Adjusted Constant Currency Revenue Growth

Vascular Access $236.8 $— $236.8 $219.1 $— $219.1 8.1% 3.3% —% 4.8%

Interventional1

204.7 — 204.7 100.2 92.6 192.8 104.4% 3.1% 98.3% 3.0%

Surgical2

106.8 — 106.8 95.0 (0.5) 94.5 12.4% 3.1% (0.6)% 9.9%

Consolidated1

$548.3 $— $548.3 $414.3 $92.1 $506.4 32.3% 3.2% 24.0% 5.1%

Notes: (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments.

(2) Adjustments are inclusive of discontinued product adjustments

See Pro Forma Adjusted Revenue by Global Product Category table for reconciliation of adjustments.

OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS

•Depreciation expense, amortization of intangible assets and deferred financing charges for the three months ended March 31, 2026 totaled $55.2 million compared to $39.5 million for the prior year period.

•Total cash, cash equivalents and restricted cash equivalents at March 31, 2026 were $329.6 million compared to $402.7 million at December 31, 2025.

•Net accounts receivable at March 31, 2026 were $365.5 million compared to $345.6 million at December 31, 2025.

•Inventories at March 31, 2026 were $380.9 million compared to $404.4 million at December 31, 2025.

2026 CONTINUING OPERATIONS OUTLOOK

On a GAAP basis, the Company continues to expect full year 2026 revenue growth from continuing operations of 14.40% to 15.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company is maintaining full year 2026 revenue growth from continuing operations of 4.50% to 5.50%.

The Company maintained its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.90 to $3.20. The Company continues to expect full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55.

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation

2025 2026 Guidance

Low High

GAAP revenue $1,992.7 $2,280 $2,300

Vascular Intervention pro forma adjustment $199.0 — —

Discontinued product adjustment $(14.3) — —

Italian payback measure adjustment $(9.0) — —

Pro forma adjusted revenue $2,168.4 $2,280 $2,300

Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation

Low High

Forecasted 2026 GAAP revenue growth 14.4% 15.4%

Vascular Intervention pro forma adjustment 10.0% 10.0%

Discontinued product adjustment (0.7)% (0.7)%

Italian payback measure adjustment (0.5)% (0.5)%

Base year adjustment (GAAP versus pro forma adjusted) 0.4% 0.4%

Estimated impact of foreign currency exchange rate fluctuations 0.7% 0.7%

Forecasted 2026 pro forma adjusted constant currency revenue growth 4.5% 5.5%

Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

Low High

Forecasted GAAP diluted earnings per share from continuing operations $2.90 $3.20

Restructuring and optimization items, net of tax $0.90 $0.90

Acquisition, integration and divestiture related items, net of tax $0.61 $0.61

Other items, net of tax $(0.65) $(0.65)

ERP implementation, net of tax $0.30 $0.30

MDR, net of tax $0.02 $0.02

Intangible amortization expense, net of tax $2.17 $2.17

Forecasted adjusted diluted earnings per share from continuing operations, net of tax $6.25 $6.55

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

A webcast of Teleflex's first quarter 2026 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on May 7, 2026.

An audio replay of the investor call will be available beginning at 11:00 am ET on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909(all other locations). The confirmation code is 69028.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.

Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.

Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency

exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.

Other - These are discrete items that occur sporadically and can affect period-to-period comparisons.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then

amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations for the three months ended March 31, 2026 and the comparable prior year period.

Q1 2026 Q1 2025

Vascular 236.8 219.1

Interventional 204.7 100.2

Surgical 106.8 95.0

GAAP revenue 548.3 414.3

Interventional - Vascular Intervention — 95.2

Interventional - Discontinued Products — (2.6)

Surgical - Discontinued Products — (0.5)

Pro forma adjusted revenue $548.3 $506.4

Vascular 236.8 219.1

Interventional 204.7 192.8

Surgical 106.8 94.5

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Three Months Ended March 31, 2026

Revenue Gross margin

SG&A (1)

R&D (1)

Operating margin (2)

(Loss) Income before income taxes Income tax expense Effective income tax rate Diluted (loss) earnings per share from continuing operations

GAAP Basis - Continuing Operations $548.3 56.1% 41.2% 8.1% 3.7% $(3.8) $1.0 (26.4)% $(0.11)

Adjustments

Restructuring and optimization charges (A) — 0.6 (1.4) — 5.0 28.0 4.4 0.54

Acquisition, integration and divestiture related items (B) — 1.4 (1.0) — 2.4 13.0 3.1 0.22

ERP implementation — — (0.7) — 0.7 3.9 0.7 0.07

MDR — — — (0.1) 0.1 0.4 — 0.01

Intangible amortization expense — 3.3 (2.9) — 6.2 33.9 4.6 0.66

Adjustments total — 5.3 (6.0) (0.1) 14.4 79.2 12.8 1.50

Adjusted basis $548.3 61.4% 35.2% 8.0% 18.1% $75.4 $13.8 18.3% $1.39

Three Months Ended March 30, 2025

Revenue Gross margin

SG&A (1)

R&D (1)

Operating margin (2)

Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations

GAAP Basis - Continuing Operations $414.3 61.7% 36.9% 6.1% 18.3% $58.8 $6.4 10.9% $1.14

Adjustments

Restructuring and optimization charges (A) — 1.1 — — 1.5 6.0 1.0 0.11

Acquisition, integration and divestiture related items (B) — — 4.4 — (4.4) (18.1) 0.8 (0.42)

ERP implementation — — (1.4) — 1.4 5.9 1.0 0.11

MDR — — — (0.2) 0.2 0.7 — 0.02

Intangible amortization expense — 3.3 (2.9) — 6.2 25.6 3.1 0.49

Tax adjustments — — — — — — 0.7 (0.01)

Adjustments total — 4.4 0.1 (0.2) 4.9 20.1 6.6 0.30

Adjusted basis $414.3 66.1% 37.0% 5.9% 23.2% $78.9 $13.0 16.4% $1.44

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

Tickmarks to Reconciliation Tables

(A)Restructuring and optimization charges – For the three months ended March 31, 2026, pre-tax restructuring charges were $16.8 million and restructuring related charges were $11.3 million. For the three months ended March 30, 2025, pre-tax restructuring charges were $1.4 million and restructuring related charges were $4.6 million.

(B)Acquisition, integration and divestiture related items – For the three months ended March 31, 2026, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of inventory step-up costs of $7.8 million and acquisition and integration costs of $7.8 million, partially offset by a benefit from contingent consideration of $2.6 million. For the three months ended March 30, 2025, these charges primarily related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of $6.2 million of acquisition and integration costs offset by the recognition of a $22.5 million benefit related to non-designated foreign currency forward contracts.

ABOUT TELEFLEX INCORPORATED

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, forecasted 2026 GAAP, pro forma adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results; statements about the pending Strategic Divestitures, the expected timetable for completing the Strategic Divestitures and the future financial and operating performance of the company following completion of the Strategic Divestitures; statements regarding our intended use of the net proceeds from the Strategic Divestitures; and statements regarding our ability to drive durable performance and long-term value for shareholders. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

Three Months Ended

March 31, 2026 March 30, 2025

(Dollars and shares in thousands, except per share)

Net revenues $ 548,262 $ 414,258

Cost of goods sold 240,836 158,827

Gross profit 307,426 0 255,431

Selling, general and administrative expenses 226,012 152,914

Research and development expenses 44,386 25,295

Restructuring charges, separation costs and impairment charges 16,845 1,422

Income from continuing operations before interest and taxes 20,183 75,800

Interest expense 25,718 18,537

Interest income (1,708) (1,488)

(Loss) income from continuing operations before taxes

(3,827) 58,751

Taxes on income from continuing operations 1,011 6,417

(Loss) income from continuing operations

(4,838) 52,334

Operating (loss) income from discontinued operations

(2,643) 50,060

Taxes on operating income from discontinued operations 673 7,392

(Loss) income from discontinued operations (3,316) 42,668

Net (loss) income

$ (8,154) $ 95,002

Earnings per share:

Basic:

(Loss) Income from continuing operations $ (0.11) $ 1.14

(Loss) Income from discontinued operations (0.07) 0.94

Net (loss) income

$ (0.18) $ 2.08

Diluted:

(Loss) Income from continuing operations $ (0.11) $ 1.14

(Loss) Income from discontinued operations

(0.07) 0.93

Net (loss) income

$ (0.18) $ 2.07

Weighted average common shares outstanding

Basic

44,257 45,782

Diluted

44,257 45,926

TELEFLEX INCORPORATED

CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, 2026 December 31, 2025

(Dollars in thousands)

ASSETS

Current assets

Cash and cash equivalents $ 309,411 $ 378,564

Accounts receivable, net 365,526 345,583

Inventories 380,861 404,395

Prepaid expenses and other current assets 149,808 150,678

Prepaid taxes 16,793 19,566

Current assets of discontinued operations 637,271 639,552

Total current assets 1,859,670 1,938,338

Property, plant and equipment, net 476,955 498,281

Operating lease assets 84,912 91,817

Goodwill 2,297,447 2,305,050

Intangibles assets, net 1,485,885 1,524,150

Deferred tax assets 12,206 12,593

Other assets 113,557 112,984

Non-current assets of discontinued operations 452,370 464,026

Total assets 6,783,002 6,947,239

LIABILITIES AND EQUITY

Current liabilities

Current borrowings $ 103,125 $ 100,000

Accounts payable 143,627 130,201

Accrued expenses 118,423 117,350

Payroll and benefit-related liabilities 103,345 124,769

Accrued interest 16,478 5,404

Income taxes payable 11,824 18,787

Other current liabilities 103,929 137,195

Current liabilities of discontinued operations 127,298 128,320

Total current liabilities 728,049 762,026

Long-term borrowings 2,514,268 2,541,449

Deferred tax liabilities 169,429 183,749

Noncurrent liability for uncertain tax positions 3,831 3,536

Noncurrent operating lease liabilities 68,320 84,210

Other liabilities 162,507 194,532

Non-current liabilities of discontinued operations 52,162 52,969

Total liabilities 3,698,566 3,822,471

Commitments and contingencies

Total shareholders' equity 3,084,436 3,124,768

Total liabilities and shareholders' equity $ 6,783,002 $ 6,947,239

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months Ended

March 31, 2026 March 30, 2025

(Dollars in thousands)

Cash flows from operating activities of continuing operations:

Net (loss) income $ (8,154) $ 95,002

Adjustments to reconcile net income to net cash provided by operating activities:

(Income) loss from discontinued operations 3,316 (42,668)

Depreciation expense 19,853 13,037

Intangible asset amortization expense 33,890 25,583

Deferred financing costs and debt discount amortization expense 1,481 851

Changes in contingent consideration (2,632) (1,795)

Stock-based compensation 6,742 6,630

Gain on non-designated foreign currency forward contracts — (23,268)

Deferred income taxes, net (12,710) (108)

Interest benefit on swaps designated as net investment hedges (8,305) (4,239)

Other 3,558 762

Changes in assets and liabilities, net of effects of acquisitions and disposals:

Accounts receivable (25,005) (10,939)

Inventories 16,473 (3,474)

Prepaid expenses and other assets 3,432 (12,724)

Accounts payable, accrued expenses and other liabilities 8,197 (17,488)

Income taxes receivable and payable, net 6,526 2,562

Net cash provided by operating activities from continuing operations 46,662 27,724

Cash flows from investing activities of continuing operations:

Expenditures for property, plant and equipment (18,791) (24,132)

Payments for businesses and intangibles acquired, net of cash acquired — (90)

Insurance settlement proceeds — 6,307

Net payments on swaps designated as net investment hedges (53,494) —

Purchase of investments (2,500) (5,000)

Net cash used in investing activities from continuing operations (74,785) (22,915)

Cash flows from financing activities of continuing operations:

Proceeds from new borrowings — 300,000

Reduction in borrowings (25,250) (49,125)

Repurchase of common stock — (300,000)

Net (payments) proceeds from share based compensation plans and related tax impacts (4,627) 7,348

Payments for contingent consideration (58) (56)

Dividends paid (15,050) (15,191)

Debt extinguishment, issuance and amendment fees — (2,500)

Net cash used in financing activities from continuing operations (44,985) (59,524)

Cash flows from discontinued operations:

Net cash provided by operating activities 2,362 45,370

Net cash used in investing activities (9,214) (5,879)

Net cash used in discontinued operations (6,852) 39,491

Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents (4,890) 5,052

Net increase in cash, cash equivalents and restricted cash equivalents (84,850) (10,172)

Cash, cash equivalents and restricted cash equivalents at the beginning of the period 453,848 327,650

Less: Cash, cash equivalents and restricted cash of discontinued operations (39,448) (35,397)

Cash, cash equivalents and restricted cash equivalents at the end of the period $ 329,550 $ 282,081

Contacts:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

610-948-2836

EX-99.2

Filename: exhibit992to5-7x2026req1.htm · Sequence: 3

exhibit992to5-7x2026req1

First Quarter 2026 Earnings Conference Call 5/7/2026 Teleflex Incorporated Exhibit 99.2

The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 7, 2026 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. Conference Call Logistics

Today’s Speakers TELEFLEX EARNINGS CONFERENCE CALL 5/7/2026 Lawrence Keusch VP, Investor Relations and Strategy Development Stuart Randle Interim President and CEO John Deren Executive VP and CFO

TELEFLEX EARNINGS CONFERENCE CALL 5/7/20264 Additional Notes This document contains certain highlights with respect to our first quarter 2026 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended March 31, 2026 located in the investor section of our website at www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the Securities and Exchange Commission. Unless otherwise noted, the following slides reflect continuing operations. This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; statements regarding our expectations with respect to the timing for closing of the sales of our Acute Care, Interventional Urology and OEM businesses (which we refer to as the “Strategic Divestitures”); statements regarding our planned uses of the net proceeds from the Strategic Divestitures, including, without limitation, with respect to the paydown of debt and the repurchase of shares our outstanding common stock; our expectation that we will be able to begin repurchasing shares of our common stock in the second quarter of 2026; statements regarding projected costs, savings and timing with respect to restructuring activities related to the Strategic Divestitures; our expectation that the transition services and manufacturing services agreements to be entered into in connection with the Strategic Divestitures will offset stranded costs on an annualized basis; our expectation that our 2027 results will provide a more representative view of our standalone, steady-state financial profile; our expectation that our Interventional business will continue to experience momentum in the second half of 2026 based on our expanded presence in cath labs and cross-selling opportunities; our expectation that our Surgical business will experience some moderation in growth in the second quarter of 2026; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward–looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation. You should not place undue reliance on these statements or the scientific data presented. Note on Forward-Looking Statements Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures, including, but not limited to, pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

Stuart Randle Interim President and CEO Executive Overview

Governance enhancements • Michael J. Tokich (former CFO, STERIS plc) nominated to Board • Plan to establish new Growth & Operating Committee • Actions underscore commitment to strong governance, thoughtful oversight, and long-term performance Planned Board transitions • Dr. Stephen Klasko and John Heinmiller to conclude their respective Board terms at upcoming annual stockholders meeting • Andrew Krakauer to succeed as Chair following Annual Meeting ◦ Current Board Compensation Committee Chair; director of Teleflex since 2018 ◦ Former CEO of Cantel Medical CEO appointment • Jason Weidman named President & CEO, effective June 8 • 25+ years of medtech experience with almost two decades at Medtronic • Proven track record in driving growth, innovation, and operational execution • Stuart Randle, Interim CEO, to remain on Board, ensuring continuity and support during transition 6 Governance Updates

Q1 Performance Summary ◦ Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50% ◦ Maintaining adjusted diluted EPS from continuing operations guidance of $6.25 to $6.55 ◦ Q1'26 pro forma adjusted constant currency revenue grew 5.1% year-over-year ◦ Q1'26 adjusted gross margin of 61.4% and adjusted operating margin of 18.1% ◦ Q1'26 adjusted EPS of $1.39, a 3.5% decrease year-over-year Q1'26 Continuing Operations Highlights 2026 Financial Guidance Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. TELEFLEX EARNINGS CONFERENCE CALL 5/7/2026

Q1'26 Global Product Commentary of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 5/7/20268 Vascular Interventional Sales ($M) Commentary • In Q1'26 growth was primarily driven by growth in our hemostatic products and in our central venous and other access portfolio Surgical • The performance for Q1'26 was driven by intraosseous, right heart catheters, and complex catheters $236.8 Reported rev. growth: 8.1% Pro forma adj. const. curr. rev. growth: 4.8% Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. Pro forma adjusted constant currency revenue growth is as compared to the prior year period. $204.7 Reported rev. growth: 104.4% Pro forma adj. const. curr. rev. growth: 3.0% $106.8 Reported rev. growth: 12.4% Pro forma adj. const. curr. rev. growth: 9.9% • Q1'26 growth was primarily driven by our ligation clip, and some timing of orders in our instrument portfolio • As expected, growth during the quarter was impacted by further integration of the Biotronik Vascular Intervention business • Continue to anticipate improving momentum in the second half of 2026 based on our expanded presence in cath labs and cross-selling opportunities • Instrument orders can be lumpy quarter to quarter, and we anticipate some moderation of growth in Q2'26

Three Months Ended March 31, 2026 March 31, 2026 March 30, 2025 % Increase / (Decrease) Reported Revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Vascular $236.8 $— $236.8 $219.1 $— $219.1 8.1% 3.3% —% 4.8% Interventional1 204.7 — 204.7 100.2 92.6 192.8 104.4% 3.1% 98.3% 3.0% Surgical2 106.8 — 106.8 95.0 (0.5) 94.5 12.4% 3.1% (0.6)% 9.9% Consolidated1 $548.3 $— $548.3 $414.3 $92.1 $506.4 32.3% 3.2% 24.0% 5.1% TELEFLEX EARNINGS CONFERENCE CALL 5/7/20269 Q1'26 Global Product Category Revenue Review Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments (2) Adjustments are inclusive of discontinued product adjustments

John Deren Executive VP and CFO Financial Overview

Q1'26 Financial Review of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 5/7/202611 Note: See appendices for reconciliations of non-GAAP financial information. SG&A Expense (% of Sales) Gross Margin R&D Expense (% of Sales) Operating Margin Earnings per Share ◦ the adverse impact of tariffs ◦ quality remediation charges primarily associated with third-party supplier disruption ◦ higher logistics and distribution costs ◦ the addition of the Vascular Intervention acquisition, which has a slightly lower gross margin than the corporate average ◦ year-over-year gross margin pressure ◦ higher operating expenses associated with the acquisition of the Vascular Intervention business as well as increased R&D investment ◦ partially offset by the positive impact of foreign exchange rates ◦ tariffs and higher interest expense ◦ partially offset by higher revenue and adjusted operating income, including the impact of the Vascular Intervention acquisition and higher R&D spending, and lower share count ◦ The year-over-year adjusted operating margin decline was driven by the following: ◦ The year-over-year adjusted gross margin decline was primarily driven by the following: ◦ The year-over-year adjusted earnings per share decrease was driven by the following: ◦ cost containment initiatives ◦ partially offset by the negative impact of foreign exchange rates ◦ The year-over-year adjusted SG&A expense % of sales decline was driven by the following: ◦ higher R&D expenses associated primarily with the Vascular Intervention acquisition ◦ The year-over-year adjusted R&D expense % of sales increase was driven by the following: (470) bps (510) bps Adjusted GAAP

12 Revenue ◦ Maintaining 2026 GAAP revenue from continuing operations growth range of 14.4% to 15.4% year-over-year ◦ Maintaining 2026 pro forma adjusted constant currency revenue growth range of 4.5% to 5.5% Earnings Per Share ◦ Maintaining 2026 GAAP EPS from continuing operations range of $2.90 to $3.20 ◦ Maintaining 2026 Adjusted diluted EPS from continuing operations range of $6.25 to $6.55 2026 Financial Guidance Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

2026 Guidance Considerations 13 Pro Forma Adj. CC Revenue Growth ◦ 4.5% to 5.5% pro forma adjusted constant currency revenue growth for 2026 Adjusted Earnings Per Share ◦ 2026 adjusted EPS from continuing operations in the range of $6.25 to $6.55 ◦ Excludes foreign exchange, Italian payback matter, and discontinued products ◦ Includes Vascular Intervention revenue for the first half of 2025 ◦ ~19.0% adjusted operating margin ◦ Annualized impact of $90 million in stranded costs ◦ $105M of interest expense ◦ Refinancing of $500M in debt (4.625% Senior Notes due 2027) ◦ No incremental debt paydown with net proceeds from sale transactions ◦ ~13.5% tax rate ◦ No material change in share count vs. 2025 ◦ No incremental share repurchase from net proceeds from sale transactions ◦ Assumes: Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

14 Adjusted Operating Margin ◦ $90m stranded costs impacting 2026 adjusted operating margin Debt Paydown ◦ Intend to pay down ~$800 million in debt, including debt associated with the Vascular Intervention acquisition, funded with net proceeds from the sale transactions Share Repurchase ◦ $1 billion share repurchase authorization primarily funded with net proceeds from the sale transactions, now expected to commence in Q2'26 2026 Financial Guidance – Future Opportunities ◦ TS/MS agreements expected to offset stranded costs on an annualized basis ◦ Announced restructuring programs to result in ~$50 million of pre-tax savings on an annualized basis upon completion in mid-2028, which will contribute to mitigating stranded costs

2026 Financial Guidance of Continuing Operations Summary TELEFLEX EARNINGS CONFERENCE CALL 5/7/202615 2026 Guidance Low High GAAP Revenue Growth 14.4% 15.4% Impact of Vascular Intervention Pro Forma 10.0% 10.0% Impact of Discontinued Product (0.7)% (0.7)% Impact of Italian Payback Measure (0.5)% (0.5)% Base Year Adjustment (GAAP Versus Pro Forma Adjusted) 0.4% 0.4% Impact of Foreign Exchange Rate Fluctuations 0.7% 0.7% Pro Forma Adjusted Constant Currency Revenue Growth 4.5% 5.5% Adjusted Operating Margin ~19% Adjusted EPS $6.25 $6.55 Adjusted EPS % Growth (10.5)% (6.2)% Note: See appendices for reconciliations of non-GAAP financial information.

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 5/7/202616 2026 Guidance 2025 2026 Guidance Low High GAAP revenue $1,992.7 $2,280 $2,300 Vascular Intervention pro forma adjustment 199.0 — — Discontinued product adjustment (14.3) — — Italian payback measure adjustment (9.0) — — Pro forma adjusted revenue $2,168.4 $2,280 $2,300 Note: See appendices for reconciliations of non-GAAP financial information.

TELEFLEX EARNINGS CONFERENCE CALL 5/7/202617 Key Takeaways Teleflex is in the midst of a transformation that is intended to optimize our portfolio, create a more focused medical technologies leader and position our company for meaningful value creation opportunities going forward. We continue to make progress on the pillars of our strategic plan, which are expected to catalyze a strong financial profile beginning in 2027. We are pleased with our Q1’26 performance, with pro forma adjusted constant currency growth of 5.1% year-over-year tracking towards our 2026 pro-forma constant currency growth guidance of 4.5% to 5.5%. In addition, the Q1'26 performance is aligned with our mid-single-digit growth profile aspirations and represents a strong reflection of the stable growth potential of our go- forward business. We continue to expect our two strategic divestitures to close in the second half of 2026, including an expectation for the OEM sale transaction to be completed in Q3'26. We remain committed to return significant capital to shareholders through our $1 billion share repurchase program, while also reducing debt to enhance our financial flexibility and support future growth and value creation. In fact, we have announced that the Company now expects to begin opportunistic share repurchases in the open market during Q2'26 rather than waiting for the close of the first strategic divestiture.

TELEFLEX EARNINGS CONFERENCE CALL 5/7/202618 Thank You!

Appendices

The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Pro forma adjusted revenue. This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. Pro forma adjusted constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. Note: Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future. Non-GAAP Financial Measures TELEFLEX EARNINGS CONFERENCE CALL 5/7/202620

Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; and (ix) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impacts of (i) restructuring and optimization charges; (ii) acquisition, integration and divestiture related items, (iii) intangible amortization expense, and (iv) Italian payback measure. Adjusted operating profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) and intangible amortization expense. Adjusted tax rate. This measure is the percentage of the Company’s adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; and (ix) tax adjustments. Non-GAAP Financial Measures TELEFLEX EARNINGS CONFERENCE CALL 5/7/202621

The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges. Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed. Non-GAAP Adjustments TELEFLEX EARNINGS CONFERENCE CALL 5/7/202622

Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance. Other - These are discrete items that occur sporadically and can affect period-to-period comparisons. European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post- market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD). Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability. Non-GAAP Adjustments TELEFLEX EARNINGS CONFERENCE CALL 5/7/202623

Appendix A1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 5/7/202624 Three Months Ended March 31, 2026 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) (Loss) Income before income taxes Income tax expense Effective income tax rate Diluted (loss) earnings per share from continuing operations GAAP Basis $548.3 56.1% 41.2% 8.1% 3.7% $(3.8) $1.0 (26.4)% $(0.11) Adjustments Restructuring and optimization charges (A) — 0.6 (1.4) — 5.0 28.0 4.4 0.54 Acquisition, integration and divestiture related items (B) — 1.4 (1.0) — 2.4 13.0 3.1 0.22 ERP implementation — — (0.7) — 0.7 3.9 0.7 0.07 MDR — — — (0.1) 0.1 0.4 — 0.01 Intangible amortization expense — 3.3 (2.9) — 6.2 33.9 4.6 0.66 Adjustments total — 5.3 (6.0) (0.1) 14.4 79.2 12.8 1.50 Adjusted basis $548.3 61.4% 35.2% 8.0% 18.1% $75.4 $13.8 18.3% $1.39 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

Three Months Ended March 30, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $414.3 61.7% 36.9% 6.1% 18.3% $58.8 $6.4 10.9% $1.14 Adjustments Restructuring and optimization charges (A) — 1.1 — — 1.5 6.0 1.0 0.11 Acquisition, integration and divestiture related items (B) — — 4.4 — (4.4) (18.1) 0.8 (0.42) ERP implementation — — (1.4) — 1.4 5.9 1.0 0.11 MDR — — — (0.2) 0.2 0.7 — 0.02 Intangible amortization expense — 3.3 (2.9) — 6.2 25.6 3.1 0.49 Tax adjustments — — — — — — 0.7 (0.01) Adjustments total — 4.4 0.1 (0.2) 4.9 20.1 6.6 0.30 Adjusted basis $414.3 66.1% 37.0% 5.9% 23.2% $78.9 $13.0 16.4% $1.44 TELEFLEX EARNINGS CONFERENCE CALL 5/7/202625 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix A2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

TELEFLEX EARNINGS CONFERENCE CALL 5/7/202626 A. Restructuring and optimization charges – For the three months ended March 31, 2026, pre-tax restructuring charges were $16.8 million and restructuring related charges were $11.3 million. For the three months ended March 30, 2025, pre-tax restructuring charges were $1.4 million and restructuring related charges were $4.6 million. B. Acquisition, integration and divestiture related items – For the three months ended March 31, 2026, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of inventory step-up costs of $7.8 million and acquisition and integration costs of $7.8 million, partially offset by a benefit from contingent consideration of $2.6 million. For the three months ended March 30, 2025, these charges primarily related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of $6.2 million of acquisition and integration costs offset by the recognition of a $22.5 million benefit related to non- designated foreign currency forward contracts. Appendix B Tickmarks

Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 5/7/202627 Forecasted GAAP Operating Margin 10.3% Estimated restructuring and optimization items 2.0% Estimated acquisition, integration and divestiture related items 1.6% Estimated separation costs 0.3% Estimated other items (1.1)% Estimated ERP implementation 0.7% Estimated MDR 0.1% Estimated intangible amortization expense 5.1% Forecasted Adjusted Operating Margin 19.0%

Appendix D - Reconciliation of Forecasted 2026 Adjusted Earnings Per Share Guidance TELEFLEX EARNINGS CONFERENCE CALL 5/7/202628 Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $2.90 $3.20 Restructuring and optimization items, net of tax $0.90 $0.90 Acquisition, integration and divestiture related items, net of tax $0.61 $0.61 Other costs, net of tax $(0.65) $(0.65) ERP implementation, net of tax $0.30 $0.30 MDR, net of tax $0.02 $0.02 Intangible amortization expense, net of tax $2.17 $2.17 Forecasted Adjusted Diluted Earnings Per Share from continuing operations, net of tax $6.25 $6.55

GRAPHIC

Filename: exhibit992to5-7x2026req1001.jpg · Sequence: 7

Binary file (76886 bytes)

Download exhibit992to5-7x2026req1001.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1002.jpg · Sequence: 8

Binary file (120897 bytes)

Download exhibit992to5-7x2026req1002.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1003.jpg · Sequence: 9

Binary file (46235 bytes)

Download exhibit992to5-7x2026req1003.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1004.jpg · Sequence: 10

Binary file (259430 bytes)

Download exhibit992to5-7x2026req1004.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1005.jpg · Sequence: 11

Binary file (34838 bytes)

Download exhibit992to5-7x2026req1005.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1006.jpg · Sequence: 12

Binary file (115010 bytes)

Download exhibit992to5-7x2026req1006.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1007.jpg · Sequence: 13

Binary file (110639 bytes)

Download exhibit992to5-7x2026req1007.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1008.jpg · Sequence: 14

Binary file (105861 bytes)

Download exhibit992to5-7x2026req1008.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1009.jpg · Sequence: 15

Binary file (92334 bytes)

Download exhibit992to5-7x2026req1009.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1010.jpg · Sequence: 16

Binary file (33489 bytes)

Download exhibit992to5-7x2026req1010.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1011.jpg · Sequence: 17

Binary file (144645 bytes)

Download exhibit992to5-7x2026req1011.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1012.jpg · Sequence: 18

Binary file (79805 bytes)

Download exhibit992to5-7x2026req1012.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1013.jpg · Sequence: 19

Binary file (119126 bytes)

Download exhibit992to5-7x2026req1013.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1014.jpg · Sequence: 20

Binary file (108681 bytes)

Download exhibit992to5-7x2026req1014.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1015.jpg · Sequence: 21

Binary file (111723 bytes)

Download exhibit992to5-7x2026req1015.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1016.jpg · Sequence: 22

Binary file (91414 bytes)

Download exhibit992to5-7x2026req1016.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1017.jpg · Sequence: 23

Binary file (121782 bytes)

Download exhibit992to5-7x2026req1017.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1018.jpg · Sequence: 24

Binary file (29871 bytes)

Download exhibit992to5-7x2026req1018.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1019.jpg · Sequence: 25

Binary file (80779 bytes)

Download exhibit992to5-7x2026req1019.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1020.jpg · Sequence: 26

Binary file (111257 bytes)

Download exhibit992to5-7x2026req1020.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1021.jpg · Sequence: 27

Binary file (152523 bytes)

Download exhibit992to5-7x2026req1021.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1022.jpg · Sequence: 28

Binary file (188749 bytes)

Download exhibit992to5-7x2026req1022.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1023.jpg · Sequence: 29

Binary file (224427 bytes)

Download exhibit992to5-7x2026req1023.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1024.jpg · Sequence: 30

Binary file (119657 bytes)

Download exhibit992to5-7x2026req1024.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1025.jpg · Sequence: 31

Binary file (119534 bytes)

Download exhibit992to5-7x2026req1025.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1026.jpg · Sequence: 32

Binary file (78959 bytes)

Download exhibit992to5-7x2026req1026.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1027.jpg · Sequence: 33

Binary file (74769 bytes)

Download exhibit992to5-7x2026req1027.jpg

GRAPHIC

Filename: exhibit992to5-7x2026req1028.jpg · Sequence: 34

Binary file (84690 bytes)

Download exhibit992to5-7x2026req1028.jpg

GRAPHIC

Filename: tfxlogo.jpg · Sequence: 35

Binary file (11320 bytes)

Download tfxlogo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 37

v3.26.1

8-K Cover Page

May 07, 2026

Cover [Abstract]

Document Type

8-K

Entity Registrant Name

TELEFLEX INCORPORATED

Document Period End Date

May 07, 2026

Entity Incorporation, State or Country Code

Entity File Number

1-5353

Entity Tax Identification Number

23-1147939

Entity Address, Address Line One

550 E. Swedesford Rd., Suite 400

Entity Address, City or Town

Wayne,

Entity Address, State or Province

Entity Address, Postal Zip Code

19087

City Area Code

(610)

Local Phone Number

225-6800

Title of 12(b) Security

Common Stock, par value $1 per share

Trading Symbol

TFX

Security Exchange Name

NYSE

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0000096943

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration